Literature DB >> 26941362

Saliva use as a lubricant for anal sex is a risk factor for rectal gonorrhoea among men who have sex with men, a new public health message: a cross-sectional survey.

Eric P F Chow1,2, Vincent J Cornelisse1,2, Tim R H Read1,2, David Lee1, Sandra Walker1,2, Jane S Hocking3, Marcus Y Chen1,2, Catriona S Bradshaw1,2, Christopher K Fairley1,2.   

Abstract

BACKGROUND: Apart from penile-anal intercourse, other anal sexual practices (rimming, fingering and saliva use as a lubricant for anal sex) are common among men who have sex with men (MSM). The aim of this study is to evaluate whether these anal sexual practices are risk factors for rectal gonorrhoea in MSM.
METHOD: A cross-sectional survey was conducted among MSM attending Melbourne Sexual Health Centre between 31 July 2014 and 30 June 2015. Rectal gonorrhoea cases were identified by culture.
RESULTS: Among 1312 MSM, 4.3% (n=56) had rectal gonorrhoea. Other anal sexual practices were common among MSM: receptive rimming (70.5%), receptive fingering or penis dipping (84.3%) and using partner's saliva as a lubricant for anal sex (68.5%). Saliva as a lubricant (adjusted OR 2.17; 95% CI 1.00 to 4.71) was significantly associated with rectal gonorrhoea after adjusting for potential confounding factors. Receptive rimming and fingering or penis dipping were not statistically associated with rectal gonorrhoea. The crude population-attributable fraction of rectal gonorrhoea associated with use of partner's saliva as a lubricant for anal sex was 48.9% (7.9% to 71.7%).
CONCLUSIONS: Saliva use as a lubricant for anal sex is a common sexual practice in MSM, and it may play an important role in gonorrhoea transmission. Almost half of rectal gonorrhoea cases may be eliminated if MSM stopped using partner's saliva for anal sex. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  GAY MEN; NEISSERIA GONORRHOEA; PREVENTION; PUBLIC HEALTH; SEXUAL BEHAVIOUR

Year:  2016        PMID: 26941362     DOI: 10.1136/sextrans-2015-052502

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  17 in total

1.  Neisseria gonorrhoeae Bacterial DNA Load in the Pharynges and Saliva of Men Who Have Sex with Men.

Authors:  Eric P F Chow; Sepehr N Tabrizi; Samuel Phillips; David Lee; Catriona S Bradshaw; Marcus Y Chen; Christopher K Fairley
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

2.  Bacterial Load of Chlamydia trachomatis in the Posterior Oropharynx, Tonsillar Fossae, and Saliva among Men Who Have Sex with Men with Untreated Oropharyngeal Chlamydia.

Authors:  Tiffany R Phillips; Christopher K Fairley; Kate Maddaford; Jennifer Danielewski; Jane S Hocking; David Lee; Deborah A Williamson; Gerald Murray; Fabian Kong; Vesna De Petra; Catriona S Bradshaw; Marcus Y Chen; Rebecca Wigan; Anthony Snow; Benjamin P Howden; Suzanne M Garland; Eric P F Chow
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

3.  Kiss and Tell: Limited Empirical Data on Oropharyngeal Neisseria gonorrhoeae Among Men Who Have Sex With Men and Implications for Modeling.

Authors:  Kyle T Bernstein; Harrell Chesson; Robert D Kirkcaldy; Julia L Marcus; Thomas L Gift; Sevgi O Aral
Journal:  Sex Transm Dis       Date:  2017-10       Impact factor: 2.830

Review 4.  [Non-viral sexually transmitted infections - Epidemiology, clinical manifestations, diagnostics and therapy : Part 1: Gonococci].

Authors:  P Nenoff; A Manos; I Ehrhard; C Krüger; U Paasch; P Helmbold; W Handrick
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

5.  Does Stigma Toward Anal Sexuality Impede HIV Prevention Among Men Who Have Sex With Men in the United States? A Structural Equation Modeling Assessment.

Authors:  Bryan A Kutner; Jane M Simoni; Kevin M King; Steven M Goodreau; Andrea Norcini Pala; Emma Creegan; Frances M Aunon; Stefan D Baral; B R Simon Rosser
Journal:  J Sex Med       Date:  2020-01-10       Impact factor: 3.802

Review 6.  Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.

Authors:  Arlene C Seña; Laura Bachmann; Christine Johnston; Teodora Wi; Kimberly Workowski; Edward W Hook; Jane S Hocking; George Drusano; Magnus Unemo
Journal:  Lancet Infect Dis       Date:  2020-06-19       Impact factor: 25.071

7.  Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections.

Authors:  Lisa A Cosentino; Claire S Danby; Lorna K Rabe; Ingrid Macio; Leslie A Meyn; Harold C Wiesenfeld; Sharon L Hillier
Journal:  J Clin Microbiol       Date:  2017-07-05       Impact factor: 5.948

8.  A Web of Complexity: Untangling the Routes of Rectal Chlamydia Acquisition.

Authors:  Christine M Khosropour; Julia C Dombrowski
Journal:  Sex Transm Dis       Date:  2018-08       Impact factor: 2.830

9.  Pharyngeal Gonorrhoea: The Willingness of Australian Men Who Have Sex with Men to Change Current Sexual Practices to Reduce Their Risk of Transmission-A Qualitative Study.

Authors:  Sandra Walker; Clare Bellhouse; Christopher K Fairley; Jade E Bilardi; Eric P F Chow
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

10.  A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol.

Authors:  Eric P F Chow; Sandra Walker; Jane S Hocking; Catriona S Bradshaw; Marcus Y Chen; Sepehr N Tabrizi; Benjamin P Howden; Matthew G Law; Kate Maddaford; Tim R H Read; David A Lewis; David M Whiley; Lei Zhang; Andrew E Grulich; John M Kaldor; Vincent J Cornelisse; Samuel Phillips; Basil Donovan; Anna M McNulty; David J Templeton; Norman Roth; Richard Moore; Christopher K Fairley
Journal:  BMC Infect Dis       Date:  2017-06-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.